Skip to content
How It Works
Explore
Resources Ask a Question
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 22 peer-reviewed journal articles Updated
Oncology

Soft Tissue Sarcoma Subtypes & Biology

At a Glance

Soft tissue sarcoma includes over 100 rare subtypes that look similar but act differently. The most important step in your care is getting a molecular diagnosis, like NGS testing, reviewed by a specialized sarcoma pathologist to ensure your treatment targets the exact genetic driver of your tumor.

Soft tissue sarcoma (STS) is not a single disease, but a complex collection of over 100 subtypes that look similar under a microscope but behave very differently in the body [1]. Because these tumors are rare and diverse, getting the right diagnosis requires more than just looking at cells—it requires looking at their genetic code.

The Shift to Molecular Diagnosis

In the past, pathologists classified sarcomas based solely on how they looked under a microscope. However, the 5th Edition WHO Classification—the global standard for cancer diagnosis—has shifted toward a molecular-first approach [2]. This means that for many sarcomas, a definitive diagnosis now requires identifying specific genetic “mistakes” [3].

Key Genetic Concepts

To understand your pathology report, it helps to know two common genetic terms:

  • Translocation: This happens when a piece of one chromosome breaks off and attaches to another chromosome [4].
  • Fusion Gene: When a translocation occurs, two normally separate genes can fuse together to create a “fusion gene.” This new gene acts like a broken light switch, stuck in the “on” position, telling the cell to grow uncontrollably [5].

Major Subtypes and Their Behaviors

Each subtype has its own biological “driver” and typical behavior. Note that GIST is biologically distinct and treated entirely differently from the others.

Subtype Biological Driver Common Behavior
Liposarcoma Often involves MDM2 or CDK4 gene amplification (extra copies) [6]. Arises from fat cells. Subtypes like ‘Well-Differentiated’ grow slowly, while ‘Dedifferentiated’ are more aggressive [7].
Leiomyosarcoma (LMS) Complex genetic changes; expresses smooth muscle markers [8]. Arises from smooth muscle tissue (like the uterus or blood vessels) [8].
Synovial Sarcoma Defined by the SS18-SSX fusion gene (a specific translocation) [5]. Often occurs near joints in young adults; despite its name, it does not actually come from joint tissue [9].
Gastrointestinal Stromal Tumor (GIST) Primarily driven by mutations in the KIT or PDGFRA genes [10]. Occurs in the digestive tract. These specific mutations make GIST highly responsive to targeted therapies (TKIs) [11].
Undifferentiated Pleomorphic Sarcoma (UPS) No single defining genetic driver; often a “diagnosis of exclusion” [12]. A high-grade, aggressive tumor that pathologists only diagnose after ruling out other specific subtypes [13].

Why Molecular Profiling is Critical

Because many sarcomas look identical under a microscope, misdiagnosis is a real risk in non-specialized settings [14][15]. Next-Generation Sequencing (NGS) is a technology that allows doctors to scan hundreds of genes at once to find the specific driver of your cancer [16].

Integrating NGS into the diagnostic process has been shown to change the diagnosis in approximately 41% of complex sarcoma cases and alter treatment plans for over 25% of patients [17]. For example, molecular testing for MDM2 amplification is the “gold standard” for distinguishing a dangerous liposarcoma from a harmless, benign fatty lump (lipoma) [18][19].

The Importance of Specialized Pathology

Sarcomas are so rare that general pathologists may only see a few cases a year. Expert review at a specialized sarcoma center is essential [1]. Studies show that patients who have their diagnosis confirmed by a specialized pathologist at a reference center have significantly better outcomes and higher survival rates than those treated only at community hospitals [20][21]. Your diagnosis is the foundation of your entire treatment plan; ensuring it is accurate through molecular testing is your most important first step [22].

Common questions in this guide

What is a soft tissue sarcoma?
Soft tissue sarcoma is not a single disease, but a collection of over 100 different cancer subtypes that arise in the body's soft tissues. Because they look similar under a microscope but behave very differently, identifying your exact subtype is crucial for treatment.
Why is molecular testing important for sarcoma?
Many sarcomas look identical under a microscope, which can lead to misdiagnosis. Molecular testing, such as Next-Generation Sequencing (NGS), identifies specific genetic mutations driving your tumor to ensure an accurate diagnosis and open up targeted treatment options.
What does translocation or fusion gene mean on my pathology report?
A translocation occurs when a piece of a chromosome breaks off and attaches to another, sometimes creating a fusion gene. This abnormal gene acts like a switch stuck in the "on" position, driving cancer growth in specific subtypes like synovial sarcoma.
Why do I need a specialized sarcoma pathologist?
Sarcomas are very rare, and general pathologists may only see a few cases a year. Having an expert sarcoma pathologist review your biopsy at a specialized center significantly improves the accuracy of your diagnosis and leads to better overall outcomes.
What is an undifferentiated pleomorphic sarcoma (UPS)?
UPS is a high-grade, aggressive type of soft tissue sarcoma without a single defining genetic driver. It is often considered a diagnosis of exclusion, meaning pathologists give this diagnosis only after molecular testing rules out other specific sarcoma subtypes.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Has my tumor been analyzed using Next-Generation Sequencing (NGS) or FISH to confirm the specific subtype?
  2. 2.Does my pathology report show an MDM2 or CDK4 amplification, and what does that mean for my prognosis?
  3. 3.Is my sarcoma a 'translocation-associated' type, and does that open up specific targeted treatment options?
  4. 4.Was my biopsy reviewed by a pathologist who specializes specifically in sarcomas?
  5. 5.How does the 5th edition WHO classification affect the way my specific diagnosis is categorized and treated?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (22)
  1. 1

    Local Control in Soft Tissue Sarcomas.

    Baldini EH, Gronchi A

    Hematology/oncology clinics of North America 2025; (39(4)):693-708 doi:10.1016/j.hoc.2025.04.011.

    PMID: 40374390
  2. 2

    The 2020 WHO Classification of Tumors of Soft Tissue: Selected Changes and New Entities.

    Choi JH, Ro JY

    Advances in anatomic pathology 2021; (28(1)):44-58 doi:10.1097/PAP.0000000000000284.

    PMID: 32960834
  3. 3

    Sarcoma classification by DNA methylation profiling.

    Koelsche C, Schrimpf D, Stichel D, et al.

    Nature communications 2021; (12(1)):498 doi:10.1038/s41467-020-20603-4.

    PMID: 33479225
  4. 4

    DDIT3 Immunohistochemistry Is a Useful Tool for the Diagnosis of Myxoid Liposarcoma.

    Scapa JV, Cloutier JM, Raghavan SS, et al.

    The American journal of surgical pathology 2021; (45(2)):230-239 doi:10.1097/PAS.0000000000001564.

    PMID: 32815829
  5. 5

    Clinical outcomes of patients with advanced synovial sarcoma or myxoid/round cell liposarcoma treated at major cancer centers in the United States.

    Pollack SM, Somaiah N, Araujo DM, et al.

    Cancer medicine 2020; (9(13)):4593-4602 doi:10.1002/cam4.3039.

    PMID: 32374488
  6. 6

    MDM2 amplification in rod-shaped chromosomes provides clues to early stages of circularized gene amplification in liposarcoma.

    Sydow S, Piccinelli P, Mitra S, et al.

    Communications biology 2024; (7(1)):606 doi:10.1038/s42003-024-06307-1.

    PMID: 38769442
  7. 7

    Survival and prognostic factors among different types of liposarcomas based on SEER database.

    Zhao J, Du W, Tao X, et al.

    Scientific reports 2025; (15(1)):1790 doi:10.1038/s41598-025-85937-9.

    PMID: 39805922
  8. 8

    Dedifferentiated Liposarcoma With Myofibroblastic Differentiation.

    Wang GY, Lucas DR

    Archives of pathology & laboratory medicine 2018; (142(10)):1159-1163 doi:10.5858/arpa.2018-0205-RA.

    PMID: 30281365
  9. 9

    Biphasic Synovial Sarcoma With Neuroendocrine Differentiation: A Case Report.

    Phillipow N, Hong B, Vanderbeck K

    The American Journal of dermatopathology 2026; (48(4)):289-293 doi:10.1097/DAD.0000000000003217.

    PMID: 41543754
  10. 10

    Liposarcoma: Multimodality Management and Future Targeted Therapies.

    Crago AM, Dickson MA

    Surgical oncology clinics of North America 2016; (25(4)):761-73.

    PMID: 27591497
  11. 11

    Recent advances in the management of liposarcoma.

    Nassif NA, Tseng W, Borges C, et al.

    F1000Research 2016; (5()):2907 doi:10.12688/f1000research.10050.1.

    PMID: 28105325
  12. 12

    [Dedifferentiated liposarcoma of extremities: a clinicopathologic analysis].

    Gong LH, Liu WF, Ding Y, et al.

    Zhonghua bing li xue za zhi = Chinese journal of pathology 2018; (47(7)):511-516 doi:10.3760/cma.j.issn.0529-5807.2018.07.006.

    PMID: 29996315
  13. 13

    The devastating impact of unresectable infectious undifferentiated pleomorphic sarcoma in the gluteal region: A case report.

    Goli R, Torabzadeh A, Hassanpour A, et al.

    International journal of surgery case reports 2024; (118()):109592 doi:10.1016/j.ijscr.2024.109592.

    PMID: 38552374
  14. 14

    Soft tissue sarcoma: Recognizing a rare disease.

    Ardakani AHG, Woollard A, Ware H, Gikas P

    Cleveland Clinic journal of medicine 2022; (89(2)):73-80 doi:10.3949/ccjm.89a.21078.

    PMID: 35105695
  15. 15

    The Midwest Sarcoma Trials Partnership: Bridging Academic and Community Networks in a Collaborative Approach to Sarcoma.

    Heater NK, Okuno S, Robinson S, et al.

    Journal of clinical medicine 2023; (12(7)) doi:10.3390/jcm12072561.

    PMID: 37048645
  16. 16

    Genomic Profiling and Clinical Outcomes of Targeted Therapies in Adult Patients with Soft Tissue Sarcomas.

    Kokkali S, Georgaki E, Mandrakis G, et al.

    Cells 2023; (12(22)) doi:10.3390/cells12222632.

    PMID: 37998367
  17. 17

    Clinical Impact of Integrating RNA-Based Next-Generation Sequencing Into the Diagnostic Evaluation of Soft Tissue Sarcomas: Insights From a Single-Center Multidisciplinary Workflow.

    Sreenath ND, Singh K, Rastogi S, et al.

    JCO global oncology 2026; (12(3)):e2500440 doi:10.1200/GO-25-00440.

    PMID: 41812090
  18. 18

    Differentiating and Categorizing of Liposarcoma and Synovial Sarcoma Neoplasms by Fluorescence in Situ Hybridization.

    Shahi F, Alishahi R, Pashaiefar H, et al.

    Iranian journal of pathology 2017; (12(3)):209-217.

    PMID: 29531545
  19. 19

    Gene Fusion Identification Using Anchor-Based Multiplex PCR and Next-Generation Sequencing.

    Cheng YW, Meyer A, Jakubowski MA, et al.

    The journal of applied laboratory medicine 2021; (6(4)):917-930 doi:10.1093/jalm/jfaa230.

    PMID: 33537766
  20. 20

    Relevance of Reference Centers in Sarcoma Care and Quality Item Evaluation: Results from the Prospective Registry of the Spanish Group for Research in Sarcoma (GEIS).

    Martin-Broto J, Hindi N, Cruz J, et al.

    The oncologist 2019; (24(6)):e338-e346 doi:10.1634/theoncologist.2018-0121.

    PMID: 30409793
  21. 21

    Comparison of the MAID (AI) and CAV/IE regimens with the predictive value of cyclic AMP-responsive element-binding protein 3 like protein 1 (CREB3L1) in palliative chemotherapy for advanced soft-tissue sarcoma patients.

    Xiao W, Liang Y, Que Y, et al.

    Journal of Cancer 2019; (10(15)):3517-3525 doi:10.7150/jca.28734.

    PMID: 31293656
  22. 22

    Intrathoracic synovial sarcoma with BRAF V600E mutation.

    Russo I, Barresi S, Di Paolo PL, et al.

    Oncotarget 2023; (14()):703-708 doi:10.18632/oncotarget.28475.

    PMID: 37417899

This page explains soft tissue sarcoma subtypes and molecular biology for educational purposes only. Always consult a sarcoma specialist and your pathology team to interpret your specific diagnosis.

Get notified when new evidence is published on Soft tissue sarcoma.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.